Future Directions in Bladder Cancer Treatment: The Experts Weigh In
Please Note: Credit Is No Longer Available
Immunotherapies are revolutionizing many cancer treatment regimens and show promise in locally advanced or metastatic bladder cancer. Immune checkpoint inhibitors are attempting to fill an unmet need in relapsed disease and biomarkers may assist in identifying patients most likely to respond. Though trial data are still evolving, mounting evidence suggests a role for immunotherapy earlier in the disease spectrum, as front-line therapy for cisplatin-ineligible patients, and in combinatorial regimens in late-stage disease. Join Drs. Neal Shore, Andrea Apolo, and Arjun Balar for this online on-demand activity as they dive into the latest data in bladder cancer therapies.
This activity is presented by Creative Educational Concepts and Bladder Cancer Advocacy Network and supported by independent educational grants from AstraZeneca and Genentech.
To complete the other activities in this series please click here.
Urology community physicians, physician assistants, nurse practitioners, nurses, and pharmacists.
- Monitor and review ongoing advanced bladder cancer trials with real time discussion of evidence-based data about new therapies.
Neal Shore, MD, FACS (Activity Chair)
Director, CPI, Carolina Urologic Research Center
Atlantic Urology Clinics
Myrtle Beach, South Carolina
Andrea B. Apolo, MD
Arjun V. Balar, MD
Director, Genitourinary Medical Oncology Program
NYU Langone Perlmutter Cancer Center
New York, New York
In accordance with the Food and Drug Administration, the speakers have disclosed that there is the potential for discussions concerning off-label uses of a commercial product/device during this educational activity.
Any person who may contribute to the content of this continuing education activity must disclose relevant relationships (and any known relationships of their spouse/partner) with commercial interests whose products or services are discussed in educational presentations. A commercial interest is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Relevant relationships include receiving from a commercial interest research grants, consultant fees, travel, other benefits, or having a self-managed equity interest in a company.
Disclosure of a relationship is not intended to suggest or condone any bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Susan H. Gitzinger, PharmD, MPA–has no financial relationships to disclose in relation to this activity. .
Kirollos S. Hanna, PharmD, BCPS, BCOP–has disclosed that he is a consultant for Seattle Genetics and is a member of the speakers' bureau for Astellas, Bristol-Myers Squibb, and Seattle Genetics.
Neal Shore, MD, FACS–has disclosed that he is a consultant and receives grant/research support from Abbvie, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Color Genomics, Dendreon, Ferring, Genentech, Genomic Health, Genzyme, Innovia, Invitae, Janssen, Merck, Myriad, Nymox, Panacea, Pfizer, Roche, Sanofi, and Tolmar.
Arjun V. Balar, MD–has disclosed that he is a consultant for AstraZeneca/Medimmune, Genentech, Immunomedics, Incyte, Janssen, Merck, Nektar, Pfizer, and Seattle Genetics. He receives grant/research support from AstraZeneca/Medimmune (institution), Genentech (institution), Immunomedics (institution), Merck (institution), Nektar, and Seattle Genetics (institution). He is a member of the Speakers' Bureau for AstraZeneca/Medimmune, Genentech, and Merck. He has equity and is a Scientific Advisory Board Member for EpiVax Oncology. He is also on the Steering/Scientific Advisory Committee for Merck and Nektar.
Andrea B. Apolo, MD–has no financial relationships to disclose in relation to this activity.
Bishoy Morris Faltas, MD–has no financial relationships to disclose in relation to this activity.
Sami Larson, PharmD–has no financial relationships to disclose in relation to this activity.
Caroline Pratz, CRNP–has no financial relationships to disclose in relation to this activity.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
CEC designates this live educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.10 CEUs) of continuing pharmacy education credit (JA0007101-0000-20-022-H01-P).
This activity is designated for 1.0 contact hour.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® NABP® CPE Monitor electronic CE tracking system.
- 1.00 ACPE Pharmacy
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation